BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Relmada Therapeutics stock surged after reporting positive Phase 2 trial results for NDV-01 and announcing a $160 million PIPE financing.
Nektar stock jumped more than 17% in premarket trading after the company reported positive 52-week data from its REZOLVE-AD atopic dermatitis trial.
RAPT Therapeutics stock surged over 63% after GSK agreed to buy the company for $58 per share in a $2.2 billion deal.
Ironwood Pharmaceuticals shares surged more than 30% in premarket trading after the company issued 2026 revenue guidance above Wall Street estimates.
Rezolute shares plunged 90% in premarket trading after its Phase 3 trial for ersodetug failed to show meaningful benefit in treating congenital hyperinsulinism.
Cogent Biosciences stock jumped 120% after positive Phase 3 PEAK trial results for its GIST drug bezuclastinib.
Artiva Biotherapeutics skyrocketed today after receiving FDA Fast Track status for its AlloNK therapy in refractory rheumatoid arthritis.
BIAFW stock jumped 52% in premarket after new case studies showed CyPath Lung can detect early-stage lung cancer.
PEPG shares jumped 114% on record-setting DM1 trial results and news of a $100M stock offering.
Shares of aTyr Pharma collapsed following disappointing Phase 3 trial results.
Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug obefazimod.
Lyra Therapeutics stock surged in premarket trading after announcing positive Phase 3 trial results for a key treatment.
Although fraught with risk, these biotech exposures bring enormous upside potential.